A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor

Blood

Volumn 120, Issue 13, 2012, Pages 2723-2732

  Navarrete, Ana Maria ^a   Casari, Caterina ^a   Legendre, Paulette ^a,b   Marx, Isabelle ^a   Hu, Jiun Ruey ^a   Lenting, Peter J ^a,b   Christophe, Olivier D ^a,b   Denis, Cécile V ^a,b  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; FIBRINOGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VON WILLEBRAND FACTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; DRUG TARGETING; IN VIVO STUDY; MESENTERY BLOOD VESSEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; THROMBOSIS;

EID: 84866847587     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-420042     Document Type: Article

References (34)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326(4):242-250.
4. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15-28. (Pubitemid 37361621)
5. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003;10(2):142-149. (Pubitemid 36207970)
6. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84(2):289-297. (Pubitemid 26040846)
7. Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des. 2007;13(26):2684-2697. (Pubitemid 47430434)
8. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knobl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106(3):539-547.
9. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;42(8):2149-2153.
10. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99(10):3623-3628. (Pubitemid 34534531)
11. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8(12):1689-1701.
12. Baruch D, Denis C, Marteaux C, Schoevaert D, Coulombel L, Meyer D. Role of von Willebrand factor associated to extracellular matrices in platelet adhesion. Blood. 1991;77(3):519-527.
13. Fressinaud E, Baruch D, Girma JP, Sakariassen KS, Baumgartner HR, Meyer D. von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. J Lab Clin Med. 1988;112(1):58-67.
14. Girma JP, Kalafatis M, Pietu G, et al. Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. Blood. 1986;67(5):1356-1366. (Pubitemid 16080606)
15. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(3):603-609.
16. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, Denis CV. Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28(3):419-424.
17. Van Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3(10):2228-2237. (Pubitemid 41727201)
18. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77(1):51-59. (Pubitemid 19125653)
19. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77(1):61-68. (Pubitemid 19125654)
20. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529. (Pubitemid 28506264)
21. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-12109. (Pubitemid 38445774)
22. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost. 1999;82(5):1382-1385. (Pubitemid 29527623)
23. Kauskot A, Adam F, Mazharian A, et al. Involvement of the mitogen-activated protein kinase c-Jun NH2-terminal kinase 1 in thrombus formation. J Biol Chem. 2007;282(44):31990-31999. (Pubitemid 350106462)
24. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost. 1990;64(2):326-332. (Pubitemid 20351890)
25. Pietu G, Ribba AS, Cherel G, et al. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb Haemost. 1994;71(6):788-792. (Pubitemid 24177971)
26. Veyradier A, Jumilly AL, Ribba AS, et al. New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor. Thromb Haemost. 1999;82(1):134-139. (Pubitemid 29368786)
27. Rayes J, Hollestelle MJ, Legendre P, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood. 2010;115(23):4870-4877.
28. Chen J, Tan K, Zhou H, et al. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol. 2008;26(1):114-119.
29. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179. (Pubitemid 36196734)
30. De Meyer SF, Staelens S, Badenhorst PN, et al. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor-collagen interaction in baboons. Thromb Haemost. 2007;98(6):1343-1349. (Pubitemid 350239108)
31. Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119(25):6128-6135.
32. Obert B, Houllier A, Meyer D, Girma JP. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib. Blood. 1999;93(6):1959-1968. (Pubitemid 29128498)
33. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3(2):125-140. (Pubitemid 36621797)
34. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22(2):323-328. (Pubitemid 34127047)